Comment on ‘Contrasting survival outcomes and patient characteristics in 5815 patients with stage II and III melanoma: a nationwide population-based registry study from Sweden’
Abstract
This comment discusses Marjanovic et al.’s study on the stage II–III melanoma survival paradox, focusing on two key aspects: the need for refined assessment of comorbidity severity and treatment disparities, and the validation of staging misclassification and micrometastasis biology. These insights aim to enhance the clinical implications of the original study and inform optimized risk-adapted management for patients with stage II–III melanoma.
Fields of Study & Subjects
Cutaneous Melanoma Detection and Management
Melanoma and MAPK Pathways
Cancer Immunotherapy and Biomarkers
Publication details
- Journal / source
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Volume
- 194
- Issue
- 5
- Pages
- 989–990
- Publication date
- 24 January 2026
- Language
- EN